Mgb Biopharma S Focus Is To Further Develop Their Completely New Class Of Anti Infective Medicinestarting With Antibiotics Based On Minor Groove Bindermgbscompounds The Company S Experienced Management Team Have Dedicated Their Initial Focus To The Development Of A New Class Of Small Moleculeswith Specific Antibacterial Activity Against Susceptible And Resistant Bacteriain Providing A New Class Of Drug To The Field Of Antibacterial Resistancebased On A Truly Novel Mechanism Of Actionmgb Biopharma Are Uniquein That A Truly New Class And Novel Moa Was Last Seen In The Year 2000 There Are Many Drugs Used To Treat Bacterial Infectionsand Generally They Belong To Classes Which Have Been In Use For Several Decadesdue To The Rise In Resistant Strains Of Bacteriaseveral Of These Drugs Are Becoming Less And Less Effective The Company S Progress Has Been Rapidand Our Lead Drug Candidatemgb Bp 3Is Currently In Phase I Clinical Safety Studieswhich Will Reach Completion At The End Of 2015Mgb Bp 3 Is Just The First In Our New Exciting Class Of Anti Infectives Mgb Biopharma Commenced Operations In 2010And Is Funded By A Syndicate Of Some Of Scotland S Leading Business Angelsin Co Operation With Scottish Enterprise
Arab Health
United Arab Emirates
27 Jan 2025
51
H7.A
| Company Name | Mgb Biopharma Ltd |
| Country |
United Kingdom
|
| Address | N/A |
| Telephone | N/A |
| N/A |
